Breaking ground in cataract surgery: Q&A with OptiMedica CEO Mark Forchette

July 9, 2012 by Arezu Sarvestani

OptiMedica CEO Mark Forchette tells MassDevice why femtosecond laser technology is changing the game in cataract surgery and how the promise of the technology lured him away from steady path at the largest ophthalmology company.

Updated: July 18, 2012 11:30 a.m.

OptiMedica CEO Mark Forchette

OptiMedica Corp. is making waves and challenging the leaders in global eye care with its Catalys Precision Laser system for cataract surgery and CEO Mark Forchette isn't shy about extolling his company's potential.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

The special sauce in contract research organization Ora Inc.'s recipe for ophthalmology trials is the eye care practice its founder started 30 years ago.

Animal rights advocacy group PETA holds a tiny stake in several medtech companies, taking frequent advantage of its shareholder rights to push changes in the way device makers experiment on animals.

AliveCor's interim-ish CEO Euan Thomson talks about the data-driven future, why he jumped ship at Accuray and how to navigate the intersection between the tempered medical device world and the wanton nimbleness of Silicon Valley.

Medtronic executive Dr. Stephen Oesterle thinks Google will be a force to be reckoned with in the medical technology space in coming years.

Roger Pontz, 1 of the first recipients of Second Sight Medical's Argus II 'bionic eye,' tells MassDevice.com about how it's changed his life.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp